Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Authors
Keywords
Antihyperglycemic agents, DPP-4 inhibitors, Fixed dose combination, GLP-1 receptor agonists, Glycemic control, SGLT2 inhibitors, Type 2 diabetes mellitus
Journal
ADVANCES IN THERAPY
Volume 35, Issue 7, Pages 939-965
Publisher
Springer Nature
Online
2018-05-18
DOI
10.1007/s12325-018-0694-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
- (2018) Richard E. Pratley et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY
- (2018) Alan J. Garber et al. Endocrine Practice
- Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge
- (2017) Richard L. Schilsky JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
- (2016) Sven Kohler et al. CLINICAL THERAPEUTICS
- Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes
- (2016) Ivan Tkáč et al. DIABETES CARE
- Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
- (2016) Samy Hadjadj et al. DIABETES CARE
- Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin
- (2016) K. Khunti et al. DIABETES OBESITY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
- (2016) Abd A. Tahrani et al. Nature Reviews Endocrinology
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
- (2016) Laurent Azoulay et al. BMJ-British Medical Journal
- Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
- (2016) Laurent Azoulay et al. BMJ-British Medical Journal
- Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
- (2016) Darren K. McGuire et al. JAMA Cardiology
- Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
- (2015) Nikolaus Marx et al. Diabetes & Vascular Disease Research
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
- (2015) Ngozi Erondu et al. DIABETES CARE
- Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
- (2015) Andrew Lewin et al. DIABETES CARE
- Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
- (2015) Ralph A. DeFronzo et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
- (2015) M. A. Abdul-Ghani et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
- (2015) André J. Scheen Expert Opinion On Drug Safety
- Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
- (2015) André J Scheen Expert Opinion On Drug Safety
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study
- (2015) Eu Jeong Ku et al. PLoS One
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
- (2014) Julio Rosenstock et al. DIABETES CARE
- Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
- (2014) Itamar Raz et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Is insulin the most effective injectable antihyperglycaemic therapy?
- (2014) J. B. Buse et al. DIABETES OBESITY & METABOLISM
- Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial
- (2014) S. A. Ross et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors in the treatment of type 2 diabetes
- (2014) Farhad M. Hasan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
- (2014) Xu-Ping Yang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy
- (2014) Swapnil N. Rajpathak et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
- (2014) Sanjay Kalra Diabetes Therapy
- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
- (2013) Wendy L. Bennett et al. ANNALS OF INTERNAL MEDICINE
- Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people
- (2013) K. Khunti et al. DIABETES CARE
- Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
- (2013) W. B. White et al. DIABETES OBESITY & METABOLISM
- Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis
- (2013) O. J. Phung et al. DIABETES OBESITY & METABOLISM
- Assessment of AACE/ACE Recommendations for Initial Dual Antihyperglycemic Therapy Using the Fixed-Dose Combination of Sitagliptin and Metformin Versus Metformin
- (2013) Samuel Engel et al. Endocrine Practice
- Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study
- (2013) T. Haak et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Urinary tract infections in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus
- (2012) Lawrence Blonde et al. ADVANCES IN THERAPY
- Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
- (2012) M. Davies et al. DIABETES CARE
- Diabetes in Older Adults
- (2012) M. S. Kirkman et al. DIABETES CARE
- Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
- (2012) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2012) T. Haak et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
- (2012) R. R. Henry et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes
- (2011) Valerie Hutchins et al. CURRENT MEDICAL RESEARCH AND OPINION
- Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
- (2011) A. J. Garber DIABETES CARE
- Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes Mellitus
- (2011) Serge Jabbour et al. POSTGRADUATE MEDICINE
- Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
- (2010) A. Maida et al. DIABETOLOGIA
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
- (2010) Juliana Levy et al. Diabetology & Metabolic Syndrome
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study
- (2009) R. A. Noel et al. DIABETES CARE
- Fixed-dose single tablet antidiabetic combinations
- (2009) C. J. Bailey et al. DIABETES OBESITY & METABOLISM
- Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
- (2009) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life
- (2009) Michael F. Pollack et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- The Decision to Intensify Therapy in Patients with Type 2 Diabetes: Results from an Experiment Using a Clinical Case Vignette
- (2009) R. W. Grant et al. Journal of the American Board of Family Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started